This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
A busy end of this week! Today, we see an approval for a new type of schizophrenia drug, we see the Biden administration back off a Medicaid proposal, and delve into what Pfizer’s withdrawal of a sickle cell drug means.
Read the rest…
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
A busy end of this week! Today, we see an approval for a new type of schizophrenia drug, we see the Biden administration back off a Medicaid proposal, and delve into what Pfizer’s withdrawal of a sickle cell drug means.
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
